Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,725.55
(
0.06%
)
News Focus
News Focus
Post# of 257484
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122926
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ghmm post# 225028

Thursday, 05/16/2019 8:45:41 PM

Thursday, May 16, 2019 8:45:41 PM

Post# of 257484
ADVM—While dose de-escalation is pretty common in a phase-1 trial (e.g. the standard "3x3" design), what we have with ADVM is unplanned de-escalation following a clinical hold. That's an altogether different story that warrants the skepticism shown in the tweets you cited.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today